Research Article

Prashant Neupane*, Sudina Bhuju, Nita Thapa, Hitesh Kumar Bhattarai

ATP Synthase: Structure, Function and Inhibition

https://doi.org/10.1515/bmc-2019-0001
received September 18, 2018; accepted December 21, 2018.

Abstract: Oxidative phosphorylation is carried out by five complexes, which are the sites for electron transport and ATP synthesis. Among those, Complex V (also known as the F<sub>0</sub>F<sub>1</sub> ATP Synthase or ATPase) is responsible for the generation of ATP through phosphorylation of ADP by using electrochemical energy generated by proton gradient across the inner membrane of mitochondria. A multi subunit structure that works like a pump functions along the proton gradient across the membranes which not only results in ATP synthesis and breakdown, but also facilitates electron transport. Since ATP is the major energy currency in all living cells, its synthesis and function have widely been studied over the last few decades uncovering several aspects of ATP synthase. This review intends to summarize the structure, function and inhibition of the ATP synthase.

Keywords: ATP, ATP Synthase, Electron Transport Chain, Proton motive force, Rotational Catalysis, ATP synthase Inhibition.

ATP: The Fuel for Life

Often referred as “molecular currency” for intracellular energy transfer, Adenosine Triphosphate (ATP) functions as a chemical fuel by powering many organic processes of life. ATP generation is the principle energy generating procedure found in all forms of life. ATP is the fuel for the operation of almost all metabolic pathways of the cell. In an ATP molecule, two high-energy phosphate bonds, called phosphoanhydride bonds, are responsible for high energy content. Hydrolysis of the third phosphate group produces adenosine diphosphate (ADP) and inorganic phosphate (Pi), along with considerable release of energy. ADP can absorb energy and regain the group to regenerate an ATP molecule to maintain constant ATP concentration.

Other than supporting almost all the cellular functions that require energy, ATP also works as a coenzyme during phosphorylation reactions. Besides, ATP has crucial role in RNA and DNA synthesis and in amino acid activation during protein synthesis. Khakh and Burnstock, established that ATP also serves as a critical signaling molecule that allows inter and intracellular communications. The ubiquitous distribution of ATP allows for signaling functions that have a uniquely broad influence on physiological functioning [1].

Estimates show that the normal body uses 40 kg of ATP on a daily basis; hence ATP production is one of the most frequent processes occurring in the body [2]. The aggregate amount of ATP in the human body is about 0.1 Mole. The energy utilized every day by an adult requires the hydrolysis of 100 to 150 Moles of ATP. This implies every ATP molecule must be reused 1000 or more multiple times in a day [3]. ATP cannot be stored and so its synthesis is closely linked to its consumption. ATP is produced under aerobic conditions through glycolysis, citric acid cycle/oxidative phosphorylation and beta-oxidation and under anaerobic condition through fermentation, photophosphorylation and replenishment reactions catalyzed by nucleoside diphosphate kinase [4].

ATP Synthase

ATP is synthesized from its precursor, ADP, by ATP synthases. These enzymes are found in the cristae and the inner membrane of mitochondria, the thylakoid membrane of chloroplasts, and the plasma membrane of bacteria [5]. Usually, there is a general understanding that ATP generation occurs in mitochondria. However, in the case of bacteria and archaea that lack mitochondria, ATP synthase is found in their plasma membrane. Additionally, ATP synthases are licensed to inhabit the chloroplast of plant cells. The structure and procedure of ATP synthesis is similar in all three locations except that light energy excites electrons enabling transmembrane movement of H<sup>+</sup> ions in...
chloroplasts. The general nomenclature of ATP synthase as \( F_0F_1 \) changes to \( CF_0CF_1 \) for chloroplast ATP synthase and \( ECF_0ECF_1 \) for \textit{Escherichia coli}'s ATP synthase [6].

ATP synthesis is the most widespread chemical reaction inside the biological world. ATP synthase is the very last enzyme in oxidative phosphorylation pathway that makes use of electrochemical energy to power ATP synthesis [7 - 10]. ATP synthase is one of the most ubiquitous and plentiful protein on the earth, accountable for the reversible catalysis of ATP to ADP and Pi. This is also one of the most conserved proteins in Bacteria, Plants and Mammals with more than 60% of the amino-acid residues of the catalytic \( \beta \)-subunit resisting evolution [11]. ATP synthases are classified as \( F \) (Phosphorylation Factor), \( V \) (Vacuole), \( A \) (Archaea), \( P \) (Proton) or \( E \) (Extracellular) ATPases based on their functional differences, although they all catalyze ATP synthesis and/or hydrolysis.

The mitochondrial ATP synthase is a multi-subunit protein complex having an approximate molecular weight of 550 kDa. The human mitochondrial ATP synthase or \( F_1/F_0 \) ATPase or complex V (EC 3.6.3.14) is the fifth component of oxidative phosphorylation chain [12]. This enzyme is the smallest known biological nanomotor and plays a crucial role in ATP generation. In plants, energy acquired from photons is transferred through photosynthetic electron transport chain (ETC), which induces an electrochemical gradient to build up across the membrane. ATP synthase uses energy conferred by this electrochemical gradient for phosphorylation of ADP to generate ATP [7].

### Electrochemical gradient and the Chemiosmotic Theory

The chemiosmotic hypothesis proposed by Peter Mitchell states: “The differential of electrochemical activity of the hydrogen and hydroxyl ions across the membrane generated by electron transport causes the specific translocation of hydroxyl and hydrogen ions from the active centre of the so called ATPase system thus effectively dehydrating ADP+P”. This pioneered the research on the coupling of the ETC and ATP synthesis. Basically, protons are pumped across the inner mitochondrial membrane as electrons pass through the electron transfer chain. This induces a proton gradient, with a decreased pH in the intermembrane space and an increased pH in the matrix of the mitochondria. The proton gradient and membrane potential are the major forces involved in ATP synthesis. Essentially, the pH gradient acts as a 'battery' which stores the electrochemical energy to be used later for ATP production.

It is well established that the electrochemical potential of protons delivered by electron transfer chains across the mitochondrial, chloroplast or bacterial membrane provides the energy for ATP synthesis [14]. Cellular respiration in the mitochondria is a widely studied process that incorporates chemiosmosis for the production of ATP. Mitochondria, the chief organelles producing ATP, are absent in prokaryotic organisms. In the absence of mitochondria, archaea and bacteria maneuver chemiosmosis to produce ATP through photophosphorylation. This process, taking place across the inner membrane, is coherent with the ETC, proton gradient, and chemiosmosis of H⁺ [15].

Electrons from NADH, FADH and other oxidizable substrates pass through the complexes of the ETC arranged asymmetrically in the inner membrane of mitochondria. Electron flow is accompanied by the transfer of protons (H⁺) across the membrane, producing both chemical gradient (ΔpH) and electric gradient (ΔΨ). The electrochemical energy built through the difference in proton concentration and separation of charge across inner mitochondrial membrane translates to the proton motive force (PMF). The PMF drives the synthesis of ATP as proton flow back into the matrix through the proton specific channels (\( F_0 \)) component of the ATP synthase.
This also satisfies a main criterion stated by Mitchell for the chemiosmotic coupling to occur: the inner mitochondrial membrane must be impermeable to protons. Thus, protons are compelled to re-enter matrix through \( F_0 \) while \( F_1 \) catalyzes the synthesis of ATP [16].

Feniouk, described ATP synthesis/hydrolysis by the reaction:

\[
\text{ATP}^4^- + H_2O \leftrightarrow \text{ADP}^3^- + P_i^2^- + P_i^2^- + H^+.
\]

ATP synthase is powered by the transmembrane electrochemical proton potential difference (\( \Delta\mu^+ \)) measured in Joules per mole (J mol\(^-1\)) and is defined as:

\[
\Delta\mu^+ = -F \Delta\Psi + 2.3 RT (pH_P - pH_N),
\]

where, \( P \) and \( N \) denote the positively and the negatively charged sides of the coupling membrane; \( F \) is Faraday constant (96 485 C mol\(^-1\)); \( R \) is the molar gas constant (8.314 J mol\(^-1\)K\(^-1\)), \( T \) is the temperature in Kelvin, and \( \Delta\Psi \) is the transmembrane electrical potential difference in volts. Protons, being charged particles, are driven by \( \Delta\mu^+ \), from the positively charged side to the negatively charged side. The value of \( \Delta\mu^+ \) gives energy required or released when 1 Mole of proton move across the membrane. During hydrolysis, the enzyme operates as ATP-driven proton pump generating \( \Delta\mu^+ \). The equation for reaction catalyzed is:

\[
\text{ADP}^3^- + P_i^2^- + nH^+\_p \leftrightarrow \text{ATP}^4^- + H_2O + (n-1)H^+\_N.
\]

\( \Delta\mu^+ \) is more conveniently replaced by proton-motive force (pmf) measured in millivolts and defined as:

\[
\text{pmf} = -\Delta\mu^+ / F = \Delta\Psi (-2.3 RT) / F (pH_P - pH_N)
\]

At room temperature (25°C),

\[
\text{pmf} = \Delta\Psi (-59) (pH_P - pH_N)
\]

The pmf value, for most biological membranes involved in ATP synthesis, lies between 120 and 200 mV (\( \Delta\mu^+ \) between 11.6 and 19.3 kJ mol\(^-1\)). This energy is capitalized by ATP synthase to catalyze the formation of ATP from ADP and inorganic Phosphate [17].

**Structural Assembly of \( F_1F_0 \) ATP Synthase**

*E.coli* ATPase/synthase comprises of 8 different subunits. There are only slight variations in its structure in the chloroplast and in the mitochondria. The chloroplast ATPase has two isoforms and in the mitochondria it has 7-9 additional subunits. Besides these differences, ATPasess are structurally and functionally similar. The ATP synthase, also called Complex V, has two major subunits designated
The structure of enzyme ATP synthase mimics an assembly of two motors with a shared common rotor shaft and stabilized by a peripheral stator stalk. The F₁ part of ATP synthase is made up of 8 subunits, 3α, 3β, γ, δ and ε, where the γ, δ and ε subunits add up to the central stalk (or the rotor shaft) and an alternate arrangement of 3α and 3β form a hexameric ring with a central cavity. The γ subunit inserted in the central cavity protrudes out to meet ε which binds on its side and together they bind the F₅.

Bacterial F₅ has the simplest subunit structure consisting α₁, β₂ and c₁₀–₁₅ subunits. Eukaryotic F₅ has several subunits including d, F₆ and the oligomycin sensitivity-conferring protein (OSCP). Subunits b, d, F₆ and OSCP form the peripheral stalk, which connect both F₁ and F₅ and keep the stators (F₁-αβ₃ and F₅-a) from spinning along with the rotor (γδε and F₅-c). Other additional subunits such as subunit e, f, g, and A6L extending over the membrane cohort with F₅ [5, 10, 20].

Rotational catalysis and ATP generation

Paul Boyer proposed a simple catalytic scheme, commonly known as the binding change mechanism, which predicted that F-ATPase implements a rotational mechanism in the
The movement of subunits within the ATP synthase complex plays essential roles in both transport and catalytic mechanisms. Each catalytic site would achieve and change three conformations during a complete 360° turnover and a cycle would be completed at a different catalytic site with a rotation of 120°. When a nucleotide binds to ATPase, it undergoes a conformational change in order to be tightly bound to ATP. Another subsequent change in conformation brings about the release of ATP. These conformational changes are accomplished by rotating the inner core of the enzyme. The core itself is powered by the proton motive force conferred by protons crossing the mitochondrial membrane.

Masamitsu et al. reviewed that 3αs and 3βs are positioned alternatingly in a circle, each having different function as well as conformation [22]. Although the α subunit has bound ATP, it neither releases the ATP nor participates in the reaction. Each β subunit has three catalytic sites that differ in nucleotide binding states [23]. The first is occupied by Mg·AMP-PNP (an analog of ATP), the second is occupied by Mg·ADP, and the third is empty (no bound nucleotide); these sites are termed βT, βD, and βE, respectively. The F1 system has inherent asymmetry within the β subunit conformations, which depend on orientation of the γ subunit. When the γ subunit rotates, it induces conformational changes in each β subunit conducive to the surface of γ subunit in contact. The rotation of the shaft (γ subunit) is effectuated by the flow of protons into the matrix through F0, which connectedly provides the energy for the release of ATP [24].

Conformational transitions that are significant in rotational catalysis are directed by the passage of protons through the F0 assembly of ATP synthase. The flow of protons through the F0 pore brings about the rotation of the cylinder of c subunits and the attached γ subunit around the axis of γ. The γ subunit runs along the central canal of the (αβ)3 assembly, which is held stationary relative to the membrane surface by the β2 and δ subunits and meets the c ring via δ and ε subunits. With every rotation of 120°, γ comes into contact with a different β subunit, and the contact forces that β subunit into the βE conformation. The three subunits switch conformations in such a way that when one holds the βE conformation, one of its flanking subunit assumes the βD form, and the other takes βT form. As a consequence of a complete rotation of the γ subunit, each β subunit courses through all three possible conformations and three ATP’s are synthesized and delivered by the enzyme.

A sturdy prediction of the binding-change model is that the γ subunit must rotate in one direction when FoF1

---

**Figure 4:** The binding-change mechanism as seen from the top of the F1 complex. There are three catalytic sites in three different conformations: loose, open, and tight. (For clarity, only the three β subunits are shown.) Substrate (ADP + P) initially binds to the open site and is converted to ATP at the tight site. In step 1, rotation of the γ subunit causes a conformational change, resulting in a change in the formation of the sites. As a result, ATP is released from the enzyme. In step 2, substrate again binds to the open site, and another ATP is synthesized at the tight site [25].
is synthesizing ATP and in the opposite direction whilst hydrolyzing ATP, was confirmed by the experiments of Masasuke Yoshida and Kazuhiko Kinosita, Jr. In biological conditions, when the concentration of H⁺ ions for F₁, motor is greater compared to F₀, motor, protons enter the matrix through the F₀ pore and the F₀ motor rotates anticlockwise to turn around F₁ thereby driving ATP synthesis. On the other hand, when the proton concentration is higher in the mitochondrial matrix, the F₁ motor reverses the F₀ motor bringing about the hydrolysis of ATP to power translocation of protons to the other side of membrane.

A team of Japanese scientists have succeeded in attaching magnetic beads to the stalks of F₁-ATPase isolated in vitro, which rotated in presence of a rotating magnetic field. F₁-ATPase synthesized ATP from ADP and Pᵢ when rotated in a clockwise direction at a rate of about 5 molecules per second. Additionally, ATP was hydrolyzed when the stalks were rotated in the counterclockwise direction or when they were not rotated at all [26].

**ATP Synthase Diseases**

Defects or mutations in this enzyme are known to cause many diseases in humans. The first defect in ATP synthase was reported by Houstek et. al.in the case of a child with severe lactic acidosis, cardiomyopathy and hepatomegaly, who died 2 days after birth. Their study indicated that this enzyme was under expressed by 70-80% and there was no observed mutation or expression deficit in the enzyme. It was postulated that mutations in some factors explicitly involved in the assembly of ATP synthase could have caused the defect [27]. Kucharczyk et. al.in their review have discussed mutations in both the nuclear and mitochondrial DNA. A mutation in one or many of the subunits in ATPase synthase can cause these diseases [28].

Mutation in α subunit has been associated with neuropathy, ataxia, retinitis pigmentosa syndrome, the familial bilateral striatal necrosis and one form of Leigh syndrome (neuromuscular disorder with a 50% survival rate to 3 year old children) [29, 30]. These diseases also result decrement in intermediary metabolism and functioning of the kidneys in removing acid from the body due to increased production of free oxygen radicals. A low expression of the β subunit and the cytosolic accumulation of the α subunit are known to cause Alzheimer’s disease. Dysfunction of F₁ specific nuclear encoded assembly factors causes selective ATPase deficiency [31]. Similar inborn defects in the mitochondrial F-ATP synthase, termed ATP synthase deficiency, have been noted where newborns die within few months or a year.

**ATP Synthase Inhibition**

Current research on ATP synthase as a potential molecular target for the treatment for some human diseases have produced positive consequences. Recently, ATPase has emerged as appealing molecular target for the development of new treatment options for several diseases. ATP synthase is regarded as one of the oldest and most conserved enzymes in the molecular world and it has a complex structure with the possibility of inhibition by a number of inhibitors. In addition, structure elucidation has opened new horizons for development of novel ATP synthase-directed agents with plausible therapeutic effects. More than 250 natural and synthetic inhibitors have been classified to date, with reports of their known or proposed inhibitory sites and modes of action [30].

We look to explore a few important inhibitors of ATP synthase in this paper. A drug, diarylquinoline (also known as TMC207) developed against tuberculosis is known to block the synthesis of ATP by targeting subunit c of ATP synthase of tuberculosis bacteria. Another such diarylquinine, Bedaquiline, is used for the treatment of multidrug resistant tuberculosis.

Among other ATP synthase inhibitors, Bz-423 is pro-apoptotic and 1,4-benzodiazepine binds the oligomycin sensitivity conferring protein (OSCP) component resulting in the generation of superoxide and subsequent apoptosis [32 - 34]. Melittin, a cationic, amphiphilic polypeptide is yet another ATP synthase inhibitor with documented inhibition of catalytic activities in mitochondrial and chloroplast ATP synthases [35].

IF1 and oligomycin are two other important classes of ATPase inhibitors. The binding of IF1, an endogenous inhibitor protein, fundamentally locks the ATP bound to the catalytic site of ATPase and restricts ATP hydrolysis. Oligomycin, an antibiotic, blocks protein channel F₀ subunit and this inhibition eventually inhibits the electron transport chain. This further prevents protons from passing back into mitochondria, eventually ceasing the operations of the proton pump, as the gradients become too high for them to operate.

Several polyphenolic phytochemicals, such as quercetin and resveratrol, have been known to affect the activity ATPase. Resveratrol and Genistein are profound non-competitive inhibitors of F0F1-ATPase. Quercetin, a flavonoid, inhibits F-ATPase and other ATPases, such as...
Na⁺/K⁺-ATPase, Ca²⁺-ATPase. At decreased concentrations, it inhibits both soluble and insoluble mitochondrial ATPase. However, it does not impact oxidative phosphorylation occurring in other mitochondrial entities [39 - 41].

Several other plant products also serve as ATPase inhibitors. Polyphenols and flavones have been found effective in the inhibition of bovine and porcine heart F₀F₁-ATPase [41, 42]. Efrapeptins are peptides which are produced by fungi of the genus *Tolypocladium* that have antifungal, insecticidal and mitochondrial ATPase inhibitory activities [43]. They target F₁ particles, especially in the α, β and γ subunits, thereby inhibiting both ATP hydrolysis and ATP synthesis in mitochondria, chloroplasts, and photosynthetic bacteria. The mode of inhibition is competitive with ADP and phosphate [30]. Another inhibitor piceatannol, a stilbenoid, has been found to inhibit the F-type ATPase preferably by targeting the F₁ subunit [39].

Another inhibitor of ATPase is bicarbonate. Bicarbonate anion acts as activator of ATP hydrolysis and Lodeyro et al. found that bicarbonate prompts ATP hydrolysis while inhibiting steady-state ATP synthesis profoundly by increasing the affinity of ATP for the catalytic site. This inhibition of ATP synthase activity was competitive with respect to ADP at low fixed phosphate concentration, mixed at high phosphate concentration and non-competitive towards Pi at any fixed ADP concentration [44].

Other inhibitors of ATPase are tenoxin, leucinostatin, fluoro-aluminate, dicyclohexyl-carbodiimide and azide. Tentoxin, a phytoxin, specifically inhibits the activity of chloroplast ATP synthases by binding at the cleft between the α and β subunits close to N-terminal beta-barrel crown of F₁ [45]. Leucinostatins bind to the F₀ part of ATP synthases and inhibit oxidative phosphorylation in mitochondria and photophosphorylation in chloroplasts [46]. Fluoro-aluminate based inhibitors bind together with ADP in catalytic sites and freeze the enzyme in a confirmation

This scheme is based on the binding change mechanism of ATP hydrolysis [36].

**Figure 5:** The inhibition of the ATP hydrolytic activity of ATP synthase by IF1. IF1 is a naturally occurring 9.6 kDa basic protein that comprises of 84 amino acids and is known to inhibit the hydrolytic activity of mitochondrial ATP synthase [37]. It acts by binding to ATP synthase at the F₁ domain in the COOH-terminal region of the β-subunit in an area which is in contact with the central γ subunit. It disrupts the contact between the β and γ subunits, thereby inhibiting the function of ATPase [38].
that presumably reflects an intermediate step of ATP hydrolysis/synthesis \[47\]. Dicyclohexylcarbodiimide (DCCD) reacts with the carboxyl group of the conserved acidic amino acid residue of subunit c at higher pH levels. However, at a lower pH (<7), DCCD modifies several carboxyl groups in F\(_1\) and inactivates it. So this compound can be considered as an inhibitor of both F\(_1\) and F\(_0\). However, inhibition of F\(_0\) is highly specific, well-defined, and requires a much lower concentration of the inhibitor \[48\]. Azide in mitochondrial F\(_0\) selectively inhibits ATPase activity by binding with MgADP (interacting with its beta-phosphate) in a catalytic site, and presumably prevents ADP release from this site, leaving its ATP synthesis activity unaffected \[49\].

The list of inhibitors that directly and indirectly inhibit the activity of ATP synthase includes, magnesium, bismuth subcitrate and omeprazole, ethidium bromide, adenylyl imidodiphosphate, arsenate, angiostatin and enterostatin, ossamycin, dequalinium and methionine, almitrine, apoptolidin, aurovertin and citreoviridin, rhodamines, venturicidin, estrogens, catechins, kaempferol, genistein, biochanin A, daidzein and continues to grow \[50 - 62\].

Conflict of interest: Authors state no conflict of interest

References

1. Khakh BS, Burnstock G. The Double Life of ATP. Scientific American. 2009;301(6):84–92.
2. Capaldi RA, Aaggeler R. Mechanism of the F(1)F(0)-type ATP synthase, a biological rotary motor. Trends in biochemical sciences. 2002;27(3):154-60.
3. Zimmermann JJ, Von Saint Andre-von Arnim A, McLaughlin J. Cellular Respiration. In: Fuhrman BP, Zimmermann JJ, Editors. Pediatric Critical Care (4th Ed.). 2011:1085-1072.
4. Bonora M, Patergnani S, Rimessi A, et al. ATP synthesis and storage. Purinergic Signal. 2012;8(3):343-57.
5. Devenish RJ, Prescott M, Rodgers AJW. The Structure and Function of Mitochondrial F1F0-ATP Synthases. International review of cell and molecular biology. 2008;267:1-58.
6. McCarty RE, Evron, Y, Johnson EA. The chloroplast ATP synthase: a rotary enzyme. Annual review of plant biology. 2000;51(1):83-109.
7. Capaldi RA, Aaggeler R, Turina P, Wilkins S. Coupling between catalytic sites and the proton channel in F1F0-type ATPases. Trends in biochemical sciences. 1994;19(7):284-289.
8. Nijtmans LG, Klement P, Houskó M, Van den Bogert C. Assembly of mitochondrial ATP synthase in cultured human cells: implications for mitochondrial diseases. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 1995;1272(3):190-198.
9. Zeviani M, Di Donato S. Mitochondrial disorders. Brain. 2004;127(10):2153-2172.
10. Ahmad Z, Cox JL. ATP Synthase: The Right Size Base Model for Nanomotors in Nanomedicine. The Scientific World Journal. 2014; 2014:567398. Published 2014 Jan 29.
11. Yoshida M, Muneyuki E, Hisabori T. ATP synthase a marvellous rotary engine of the cell. Nature Reviews Molecular Cell Biology. 2001;2(9):669-677.
12. Jonckheere AI, Smeltink JA, Rodenburg RJ. Mitochondrial ATP synthase: architecture, function and pathology. Journal of Inherited Metabolic Disease. 2011;35(2):211-225.
13. Rigoulet M, Mourier A, Devin A. Organization and Regulation of Mitochondrial Oxidative Phosphorylation. In Prof. Valdur Saks, Editor. Molecular System Bioenergetics: Energy for Life. New Jersey: John Wiley & Sons, Inc; 2007:29-58.
14. Senior, AE, Nadanaciva S, Weber J. The molecular mechanism of ATP synthesis by F1F0-ATP synthase. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2002;1553(3):188-211.
15. Schäfer G, Engelhard M, Müller V. Bioenergetics of the Archaea. Microbiology and Molecular Biology Reviews. 1999;63(3):570-620.
16. Nelson DL, Cox MM. Lehninger Principles of biochemistry,5th Ed. NewYork: WH Freeman and Company; 2008.
17. Feniouk BA. ATP Synthase FAQ. Web site. http://www.atpsynthase.info/FAQ.html. Published 2012. Accessed March 26, 2018.
18. McCarty RE. A plant biochemist’s view of H+–ATPases and ATP synthases. Journal of Experimental Biology. 1992;172(1):431-441.
19. Noji H, Yoshida M. The rotary machine in the cell, ATP synthase. Journal of Biological Chemistry. 2001;276(3):1665-1668.
20. Walker JE, Dickson VK. The peripheral stalk of the mitochondrial ATP synthase. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2006;1757(5-6):286-296.
21. Boyer PD. The binding change mechanism for ATP synthase - some probabilities and possibilities. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 1993;1140(3):215-250.
22. Masamitsu F, Mayumi N, Okamoto H, Sekiya M, Nakamoto RK. Rotational catalysis in proton pumping ATPases: From E. coli F–ATPase to mammalian V–ATPase. Biochimica et Biophysica Acta (BBA) – Bioenergetics. 2012;1817(10):171-1721.
23. Abrahams JP, Leslie AGW, Lutter R, Walker JE. Structure at 2.8 Å resolution of F1. Nature. 1994;64(2):10-12.
24. Nakamoto RK, Scanlon JAB, Al-Shawi MK. The rotary mechanism of the ATP synthase. Archives of biochemistry and biophysics. 2008;476(1):43-50.
25. Duncan TM, Bulygın VV, Zhou Y, Hutcheon ML, Cross RL. Rotation of subunits during catalysis by Escherichia coli F1-ATPase. Proceedings of the National Academy of Sciences of the United States of America. 1995;92(24):10964–10968.
26. Itoh H, Takahashi A, Adachi K, Noji H, Yasuda R, Yoshida M, et al. Mechanically driven ATP synthesis by F1-ATPase. Nature. 2004;427(6973):465-468.
27. Houštek J, Klement P, Floýr D, Antonická H, Hermanská J, Kalous M, et al. A novel deficiency of mitochondrial ATPase of nuclear origin. Human molecular genetics. 1999;8(11):1967-1974.
28. Kucharczyk R, Zick M, Blondel M, et al. Mitochondrial ATP synthase disorders: molecular mechanisms and the quest for curative therapeutic
approaches. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2009;1793(1):186-199.
29. de Vries DD, van Engelen BG, Gabriëls Fj, Ruitenbeek W, van Oost BA. A second missense mutation in the mitochondrial ATPase 6 gene in Leigh’s syndrome. Annals of neurology. 1993;34(3):410-412.
30. Hong S, Pedersen PL. ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas. Microbiology and Molecular Biology Reviews. 2008;72(4):590-641.
31. Houšťek J, Mráček T, Vojišťková A, Zeman J. Mitochondrial diseases and ATPase defects of nuclear origin. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2004;1658(1-2):115-121.
32. Johnson KM, Chen X, Boitano A, Swenson L, Opipari AW, Gluck GD. Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423. Chemistry & biology. 2005;12(4):485-496.
33. Blatt NB, Bednarski, JJ, Warner RE, Leonetti F, Johnson KM, Boitano A, et al. Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insight and potential therapeutic utility. The Journal of clinical investigation. 2002;110(8):1123-1132.
34. Blatt NB, Boitano AE, Lyssiotis CA, Opipari AW, Gluck GD. Bz-423 superoxide signals B cell apoptosis via Mcl-1, Bak, and Bax. Biochemical pharmacology. 2009;78(8):966-973.
35. Datiles MJ, Johnson EA, McCarty RE. Inhibition of the ATPase activity of the catalytic portion of ATP synthases by cationic amphiphiles. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2008;1777(4):362-368.
36. Cabezón E, Butler PJ, Runswick MJ, Carbajo RJ, Walker JE. Homologous and heterologous inhibitory effects of ATPase inhibitor proteins on F-ATPases. J. Biol. Chem. 2002;277:41334-41341.
37. Pullman ME, Monroy GC. A Naturally Occurring Inhibitor of Mitochondrial Adenosine Triphosphatase. The Journal of Biological Chemistry. 1963;283(11):3762-3769.
38. Cabezón E, Montgomery MG, Leslie AG, Walker JE. The structure of bovine F1-ATPase in complex with its regulatory protein IF 1. Nature Structural and Molecular Biology. 2003;10(9):744-750.
39. Zheng J, Ramirez VD. Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals. British Journal of Pharmacology. 2000;130(5):1115-23.
40. Fewtrell CMS, Gomperts BD. Quercetin: A novel inhibitors of mitochondrial energy-linked functions by arsenate: Evidence for a non hydrolytic mode of inhibitor action. Biochemistry. 1971;10:2049-2054.
41. Moser TL, Stack MS, Aspin, I, Enghild JJ, Hojrup J, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. 1999; 96:2811–2816.
42. Perlin DS, Latchney LR, Senior AE. Inhibition of Escherichia coli H-ATPase by venturicidin, oligomycin and oomycace. Biochim. Biophys. Acta.1985;807:23-36.
43. Krasnoff SB, Gupta S, Leger RJ, Renwick JAA, Roberts DW. Antifungal and insecticidal properties of the efrapeptins: Metabolites of the fungus Tolypocladium niveum. Journal of Invertebrate Pathology. 1991;58(2):180-188.
44. Lodeyro A, Calcaterra N, Roveri O. Inhibition of steady-state mitochondrial ATP synthesis by bicarbonate, an activating anion of ATP hydrolysis. Biochimica et biophysica acta. 2001;1506(3):236-243.
45. Arntzen, Cj. Inhibition of photophosphorylation by tentoxin, a cyclic tetrapeptide. Biochimica et biophysica acta. 1972;283(3):539-542.
46. Satelli L, Lloyd D. Effects of inhibitors on mitochondrial adenosine triphosphatease of Crichtidia fasciculata: an unusual pattern of specificities. Molecular and Biochemical Parasitology. 1981;3(1):13–17.
47. Feniouk BA, Skulachev VP. Cellular and Molecular Mechanisms of Action of Mitochondria-Targeted Antioxidants. Current aging science. 2016;10(1):41-48.
48. Weber J, Senior AE. Effects of the inhibitors azide, dicyclohexylcarbodimide, and aurovertin on nucleotide binding to the three F1-ATPase catalytic sites measured using specific tryptophan probes. The Journal of Biological Chemistry. 1998;273:33210–33215.
49. Bowler MW, Montgomery MG, Leslie AG, Walker JE. How azide inhibits ATP hydrolysis by the F1-ATPases. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(23):8646-8649.
50. Ahmad Z, Senior AE. Inhibition of the ATPase activity of Escherichia coli ATP synthase by magnesium fluoride. FEBS Letters. 2006;580(2):517 – 520.
51. Bell, W, Birko1zol C, Wagner S, Sewing KF. Bismuth subcitrate and omeprazole inhibit Helicobacter pylori F1-ATPase. Pharmacology.1995;50(5):333–337.
52. Crosby B, Boulty M, Goffeau A. Inhibition of soluble yeast mitochondria ATPase by ethidium-bromide. Biochemical and Biophysical Research Communications. 1979;88(2):448-455.
53. Gresser Ml, Beharry S, Moennich DM. Inhibition of mitochondrial F1-ATPase by adenyl imidodiphosphate. Curr. Top. Cell. Regul. 1984;24:365–378.
54. Mitchell RA, Chang BF, Huang CH, DeMaster EG. Inhibition of mitochondrial energy-linked functions by arsenate: Evidence for a non hydrolytic mode of inhibitor action. Biochemistry. 1971;10:2049–2054.
55. Moser TL, Stack MS, Aspin, I, Enghild JJ, Hojrup J, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc. Natl. Acad. Sci. 1999; 96:2811–2816.
56. Perlin DS, Latchney LR, Senior AE. Inhibition of Escherichia coli H-ATPase by venturicidin, oligomycin and oomycace. Biochim. Biophys. Acta.1985;807:23-36.
57. Ren HM, Allison WS, Photoinactivation of the F1-ATPase from spinach chloroplasts by dequalinium is accompanied by derivatization of methionine 183. J. Biol. Chem.1997; 272:32294–32300.
58. Rigoulet M, Ouhabi R, Leverve X, Putod-Paramelle F, Guerin B. Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim. Biophys. Acta. 1998;975:325–329.
59. Salomon AR, Voehringer DW, Herzenberg LA, Khosla C. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem. Biol. 2001;8:71–80.
60. Wieker HJ, Kuschmzitz D, Hess B. Inhibition of yeast mitochondrial F1-ATPase, F0F1-ATPase and submitochondrial particles by rhodamines and ethidium bromide. Biochim. Biophys. Acta.1987;892:108–117.
61. Zhang S, Letham DD, Jagendorf AT. Inhibition of thylakoid 
ATPase by venturicidin as an indicator of CF1-CF0 interaction. 
Plant Physiol. 1993;101:127–133.

62. Zheng J, Ramirez VD. Rapid inhibition of rat brain mitochondrial 
proton F0F1-ATPase activity by estrogens: comparison with Na, 
K-ATPase of porcine cortex. Eur. J. Pharmacol. 1999;368:95–102.